Medical Device Startup Funding Closes Faster When Category Work Happens Pre-Seed

Medical device startup funding closes faster when category work happens at pre-seed, before the FDA clearance conversation even starts. Founders who wait until clearance to build a narrative are fundraising with half the story.

I've sat across from founders at every stage of this, and the ones who treat category and narrative as pre-seed work close rounds the ones who don't spend a year chasing.

Key Takeaways

• Medical device startup funding has a documented gap right after FDA clearance, when companies are pre-commercial and hardest to fund.
• The traction gap between a cleared device and a market that has formed is what investors price into a term sheet on top of the clinical data.
• Series A investors resist funding PMA-pathway companies before a pivotal trial, because nobody wants to fund the early clinical development that follows, so Series A investors end up carrying it.
• Category and narrative work done before the raise shortens the traction gap investors are underwriting against.
• M&A liquidity loosens seed and Series A risk budgets industry-wide, but it doesn't replace category work at the company level.
• The strongest medical device startup funding conversations start with a defined category as well as a cleared product.

Why Medical Device Startup Funding Has a Gap Right After Clearance

Medical device startup funding has a well-documented gap right after FDA clearance, when a company is pre-commercial and hardest to fund. Seed capital from friends, family, and grants is rarely the hard part. What comes next is.

I interviewed Todd Usen on an episode about running a public company versus a medtech startup. He named the gap directly:

"There seems to be kind of like a no man's land of funding for medtech companies these days. Raising initial seed capital through friends and family or grants is not an issue.

But there's a moment where it's usually when a company is right after FDA approval, but they're pre-commercial where almost nobody wants to touch them."

Venture capitalists are dealing with their own version of that gap. Limited partners have gotten more selective about funding companies that aren't already in growth stage or generating commercial traction.

That squeeze pushes the funding gap earlier in the company's life, right onto the founders who haven't built a category or a narrative yet to carry them through it.

How Series A Investors Think About PMA-Pathway Risk

Series A investors resist funding PMA-pathway medical device companies before a pivotal trial, because nobody wants to fund the early clinical development that follows, so Series A investors end up carrying it themselves.

I interviewed Jonathan Norris, Managing Director at HSBC Innovation, on an episode about the 2024 medtech investing outlook. He explained the mechanics from the investor's side:

"If you have a PMA pathway company and an impending pivotal trial that you're going to have to raise money for down the road, it's really hard to find a Series A group that's willing to put that money out the door to get that initial product underway.

Nobody wants to come in for Series B, because Series B is not pivotal trial funding. It's early clinical development. Why would I come in at that point? Why wouldn't I just want to wait till you get your pivotal clinical trial?"

That leaves early Series A investors carrying a bigger share of the risk than the label on the round suggests. A defined category and a clear narrative are what convince them the risk is underwritable at all.

How Category Work Shortens the Traction Gap Investors Underwrite

Category and narrative work done before a raise shortens the traction gap that investors are pricing into every term sheet. A defined category gives an investor context before they ask for it.

The traction gap is the distance between a clinically valid device and a market that has formed around it. Investors don't fund clinical validity alone. They fund evidence that a category exists and buyers already recognize it.

Shockwave Medical is the clean example of what the funding arc looks like when the company earns conviction early. I interviewed Daniel Hawkins, founder of Shockwave Medical, on an episode about leading Shockwave and Avail Medsystems. He described the start of it directly:

"On that day, January 15, 2009, we started Shockwave and we got seed funding of a few hundred thousand dollars.

Did a whole bunch of experiments, enough proof point that I was able to go back to Fred Ball, tell them about it, and Fred led a Series A angel round of four million dollars."

Proof of concept plus a founder who could tell the story clearly got Hawkins a four million dollar angel round led by Fred Ball.

Founders who skip the category and narrative work ask investors to underwrite the full traction gap themselves. Founders who've done that work are asking for capital to execute a plan investors already understand.

Why M&A Liquidity Changes What Founders Can Raise For

M&A liquidity loosens seed and Series A risk budgets across medtech, and it changes what gets funded industry-wide while leaving what any single founder has to build at the company level untouched.

"If liquidity is the mother of courage, I'd say when exits are possible, founders attempt the impossible. And when founders attempt the impossible, somebody's going to be willing to fund it."

I said that on an episode about how mini strategics are winning $100B in exits. When the exit market loosens, investors get bolder further upstream, and seed and Series A checks follow.

That industry-level tailwind still doesn't substitute for category and narrative work at the individual company level. A looser fundraising environment gets more founders in the room. It doesn't get any single founder a category buyers already recognize.

The founders who benefit most from a loosening cycle are the ones who already did the category work and are simply waiting for the capital to catch up to a story they can already tell clearly.

What This Means for Medtech Founders

In my experience working with medtech founders, medical device startup funding is a narrative problem that starts well before clearance. Most founders treat it as a milestone to hit, then raise on.

If you're pre-clearance, start the category and narrative work now, in parallel with the regulatory pathway instead of after it. The traction gap investors price into your round is smaller when you walk in with both.

If you're post-clearance and stuck in the no-man's-land gap Todd Usen described, look first at whether your category and narrative are legible to an investor who's never met you before you assume it's a capital-markets problem.

I'd also tell founders heading into their first institutional raise: name your category before you name your ask. Investors fund a company they can place inside a market they already understand.

Read more on this in what investors really want to see in a medtech Series A and in how to build a medtech investor narrative that carries a round through the gap.

Frequently Asked Questions

How hard is it to raise medical device startup funding right after FDA clearance?

It's one of the hardest points in the funding lifecycle. Seed capital from friends, family, and grants is usually accessible. The gap opens right after clearance, when a company is pre-commercial and investors want to see growth-stage traction before committing more capital.

Why won't Series A investors fund PMA-pathway companies before a pivotal trial?

Because nobody wants to fund the early clinical development that follows, investors would rather wait for pivotal trial data. That leaves the earliest Series A investors carrying more of the clinical risk than later rounds typically do.

What is the traction gap in medical device startup funding?

The traction gap is the distance between a clinically valid device and a market that has formed around it. Investors fund evidence that a category exists and buyers recognize it, and category and narrative work done early shortens that gap.

Does M&A activity make medical device startup funding easier to raise?

It loosens risk budgets industry-wide, which makes investors bolder at the seed and Series A stage. But it changes the environment and leaves the individual company's story untouched. A defined category and narrative still determine whether any single founder gets funded inside that looser market.

Where to Go From Here

If you're doing this yourself. Use the Pitch Deck Analyzer to see where your narrative leaves gaps an investor would have to fill in themselves, and check the MedTech Investor List for funds active at your stage.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. It maps whether your category and narrative are ready for the raise you're about to run.

Listen to the Full Conversations

• Running a Public Company vs Medtech Startup with Industry Veteran Todd Usen
• 2024 Medtech Investing Outlook with Jonathan Norris, Managing Director at HSBC Innovation
• Leadership: Daniel Hawkins, Founder of Shockwave Medical & Avail Medsystems
• $100B Exit Fix: How Mini Strategics Are Winning!

Subscribe to The State of MedTech wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.